Blood and Marrow Transplant

Blood and Marrow Transplant

The mission of the Blood and Marrow Transplant (BMT) program in the Taussig Cancer Institute is to provide high-quality, specialized patient care that emphasizes innovation, collaboration, research, and empathy. The leading edge 22-bed BMT floor features elements specifically designed for an immune-compromised patient population, including a centralized air-handling system, dedicated facilities for caregivers, and amenities to ease the burden of a 3- to 6-week average hospital stay. Cleveland Clinic's BMT program is accredited by the Foundation for the Accreditation of Cellular Therapy, and maintains associations with the National Marrow Donor Program, the Blood and Marrow Transplant Clinical Trials Network, the Chronic Graft vs Host Disease Consortium, the Radiation Injury Treatment Network, the SWOG, and the Center for International Blood and Marrow Transplant Research®.

Survival 100 Days After Autologous Hematopoietic Cell Transplantation for Patients With Myeloma and Lymphoma (N= 237)

2016-2017

Cleveland Clinic's 100-day survival outcomes of 98% for patients with myeloma and 95% for patients with lymphoma are similar to national benchmarks.

Survival 100 Days After Allogeneic Hematopoietic Cell Transplantation Using Related Donor for Patients With Acute/Chronic Leukemia and Myelodysplastic Syndromes (N= 23)

2016-2017

Cleveland Clinic's 100-day survival outcomes of 79% of patients receiving myeloablative conditioning and 100% for patients receiving reduced intensity conditioning for related donor hematopoietic cell transplantation for acute/chronic leukemia and myelodysplastic syndromes are similar to national benchmarks.

Survival 100 Days After Allogeneic Hematopoietic Cell Transplantation Using Unrelated Donor for Patients With Acute/Chronic Leukemia and Myelodysplastic Syndromes (N= 68)

2016-2017

Cleveland Clinic's 100-day survival outcomes of 88% for patients receiving myeloablative conditioning and 95% for patients receiving reduced intensity conditioning for unrelated donor allogeneic hematopoietic cell transplantation for acute/chronic leukemia and myelodysplastic syndromes are similar to national benchmarks.

Survival 100 Days After Allogeneic Hematopoietic Cell Transplantation Using Haploidentical Donor for Patients With Acute/Chronic Leukemia and Myelodysplastic Syndromes (N= 22)

2016-2017

Cleveland Clinic's 100-day survival outcomes of 92% for patients receiving myeloablative conditioning and 100% for patients receiving reduced intensity conditioning for haploidentical donor allogeneic hematopoietic cell transplantation for acute/chronic leukemia and myelodysplastic syndromes is similar to the national benchmark.